NCT02832947View on ClinicalTrials.gov

PK of Rivaroxaban in Bariatric Patients - Extension

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

October 31, 2016

Conditions
Prophylaxis of Venous Thromboembolism
Interventions
DRUG

Rivaroxaban 10 mg

At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.

Trial Locations (1)

3010

University Hospital, Inselspital Berne, Bern

All Listed Sponsors
collaborator

University of Lausanne Hospitals

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT02832947 - PK of Rivaroxaban in Bariatric Patients - Extension | Biotech Hunter | Biotech Hunter